Anti-CD20 monoclonal antibody drugs are laboratory-made proteins designed to latch onto a molecule called CD20 on the surface of B cells, a type of white blood cell, and trigger their destruction. Rituximab, approved in 1997 as the first monoclonal antibody ever used to treat cancer, remains the most widely known member of this drug class. Since then, several newer anti-CD20 antibodies have been engineered with modifications meant to improve how effectively they clear B cells. These drugs are now used across a surprisingly wide range of conditions, from blood cancers to multiple sclerosis to rheumatoid arthritis, making them one of the most versatile drug families in modern medicine.
Why Target CD20?
CD20 is a protein that sits in the outer membrane of most B cells. It first appears during a relatively early stage of B-cell development and stays on the surface through most of a B cell’s life. It disappears only at the very end, once a B cell matures into an antibody-secreting plasma cell. That timing is useful for therapy because it means anti-CD20 drugs can wipe out a broad swath of B cells while leaving antibody-producing plasma cells partially intact, preserving at least some existing immune protection.
Researchers have also found that CD20 expression varies across different B-cell cancers. Certain lymphomas express high levels of CD20 on their surfaces, while chronic lymphocytic leukemia (CLL) cells tend to express relatively less.
Despite decades of study, CD20’s exact biological function remains somewhat mysterious. Knocking it out in lab experiments does not seem to impair B-cell receptor signaling, survival, or proliferation. Instead, researchers have found that losing CD20 disrupts the cell’s internal scaffolding, impairing its ability to move toward chemical signals and stick to other surfaces.
How These Drugs Destroy B Cells
Once an anti-CD20 antibody binds to CD20 on a B cell’s surface, it can trigger cell death through several overlapping pathways. The relative importance of each pathway has been debated for years, and the answer likely differs depending on where in the body the B cells are and which specific drug is used.
- Phagocytosis: Immune cells called macrophages engulf and digest the antibody-coated B cell. In mouse studies and in-vitro work with human cells, this appears to be a dominant clearance route. One study comparing four different anti-CD20 antibodies found that macrophage-driven phagocytosis was at least ten-fold more effective at depleting CLL cells per effector cell than killing by natural killer cells.
- Complement activation: The antibody triggers a cascade of blood proteins called complement, which punch holes in the B cell’s membrane. Not all anti-CD20 drugs are equally good at this. The distinction partly comes down to whether the drug is classified as “type I” or “type II,” based on how it rearranges CD20 molecules on the cell surface after binding.
- Natural killer cell activity: NK cells recognize the tail end of the antibody sticking off the B cell and release toxic granules that kill it. This mechanism, called antibody-dependent cellular cytotoxicity, was originally thought to be the primary way these drugs worked, but more recent evidence has shifted emphasis toward phagocytosis.
- Direct cell death: Some anti-CD20 antibodies, particularly type II antibodies, can trigger a form of programmed cell death without needing help from other immune cells at all.
Live imaging experiments have added nuance to this picture. When researchers tracked anti-CD20 therapy in real time in mice, macrophages in the bone marrow were the primary killers, but their activity plateaued after roughly an hour, leaving some tumor cells behind.
Type I Versus Type II Antibodies
Anti-CD20 antibodies are classified into two functional types based on how they behave once they bind. Type I antibodies, which include rituximab and ofatumumab, push CD20 molecules together into clusters called lipid rafts on the cell surface. This clustering is what makes them effective at activating complement. Type II antibodies, such as obinutuzumab, do not cluster CD20 as efficiently and are weaker at triggering complement. Instead, they are better at directly inducing cell death upon binding.
Lab studies comparing how complement component C1q interacts with cells coated by different antibodies found that ofatumumab produced more stable C1q binding than rituximab, while obinutuzumab generated too little C1q binding to measure clearly. This helps explain why ofatumumab was developed partly on the promise of stronger complement-mediated killing, while obinutuzumab went in a different engineering direction entirely.
Generations of Anti-CD20 Drugs
Rituximab, approved in late 1997, was a chimeric antibody, meaning part of its structure came from mouse protein and part from human protein. It was the first monoclonal antibody approved by the FDA for the treatment of any cancer and was initially indicated for a type of non-Hodgkin lymphoma. Its success opened the door for everything that followed.
Ofatumumab came next as a fully human antibody that binds a different spot on CD20 than rituximab does. Preclinical data suggested it produced stronger complement-dependent killing and cellular cytotoxicity compared with rituximab. It was initially approved for CLL patients who had not responded to other therapies and has since gained approval for relapsing forms of multiple sclerosis.
Obinutuzumab represents a different engineering philosophy. Rather than changing where the antibody grabs CD20, its developers modified the antibody’s tail, the Fc region that communicates with immune cells. Specifically, they removed a sugar molecule called fucose from the Fc domain. This seemingly small tweak roughly sevenfold increased the antibody’s binding affinity for a receptor on immune cells called CD16, which is the receptor NK cells and neutrophils use to recognize antibody-coated targets. The practical result is that obinutuzumab triggers substantially stronger phagocytosis and NK cell killing than rituximab does.
Lab work has shown that obinutuzumab’s high-affinity binding to CD16 on NK cells leads to enhanced production of interferon-gamma, a signaling molecule that amplifies the immune response, compared with rituximab. This enhanced activation occurred regardless of which genetic variant of CD16 the donor’s NK cells carried, a detail that matters because genetic differences in CD16 are one reason patients respond differently to rituximab.
Cancer Indications
Anti-CD20 antibodies are foundational treatments across several blood cancers. Rituximab has demonstrated effectiveness in both slow-growing (indolent) lymphomas like follicular lymphoma and aggressive types like diffuse large B-cell lymphoma, as well as in CLL. In most cancer settings, the antibody is combined with chemotherapy rather than used alone, and this combination has improved response rates and, in many cases, survival compared with chemotherapy alone.
Despite their established role, a meaningful fraction of patients do not respond to anti-CD20 therapy or eventually stop responding after initial success. The reasons for resistance remain incompletely understood, which is a notable gap given how widely these drugs are used. Proposed explanations include loss of CD20 expression on the tumor surface, consumption of complement proteins faster than the body can replenish them, and shielding of the antibody’s Fc region by inhibitory receptors on immune cells. No single mechanism has emerged as the dominant explanation, and for many patients who relapse, the cause of treatment failure is simply unknown.
Beyond Cancer
The realization that B cells play important roles in autoimmune disease, not just by producing harmful antibodies but also by presenting foreign molecules to other immune cells and releasing inflammatory signals, expanded the use of anti-CD20 drugs far beyond oncology.
In multiple sclerosis, large clinical trials have shown that B-cell depletion with anti-CD20 antibodies reduces relapses in relapsing MS. Perhaps more strikingly, ocrelizumab (another anti-CD20 drug) became the first therapy shown to be effective in primary progressive MS, a form of the disease that had resisted nearly every other treatment approach. B-cell depletion is now considered an essential treatment option in MS based on its benefit-to-risk balance.
In rheumatoid arthritis, rituximab has been used for patients who do not respond adequately to other biologic therapies. It has also shown usefulness in rarer complications. In a registry of nearly 2,000 rheumatoid arthritis patients, 17 who developed systemic vasculitis, a dangerous inflammation of blood vessels, were treated with rituximab. After six months, roughly seven in ten achieved complete remission of their vasculitis, and by twelve months, that number had risen to over eight in ten. Rituximab has also been used to simultaneously treat vasculitis and rheumatoid arthritis in patients who have both conditions, simplifying what would otherwise be a complicated treatment regimen.
Other autoimmune conditions where anti-CD20 drugs see use, either with formal regulatory approval or off-label, include certain kidney diseases, autoimmune blood disorders, and some forms of peripheral neuropathy. The breadth of applications keeps growing as researchers better understand the role B cells play in driving immune dysfunction.
How They Are Given
Rituximab was originally administered only by intravenous infusion, which typically takes two to three hours per session (sometimes longer for the first infusion, when reactions are most common). More recently, a subcutaneous formulation has become available. In a randomized trial comparing the two routes in patients with diffuse large B-cell lymphoma, the subcutaneous injection achieved similar response rates to the IV infusion but took a median of just six minutes to administer, compared with roughly two and a half to three hours for the IV version. Safety profiles were comparable, and patients reported greater satisfaction with the subcutaneous route.
A separate trial in CLL patients confirmed that the subcutaneous formulation delivered drug levels at least as high as the intravenous version, with the subcutaneous group actually achieving higher trough concentrations. Adverse event rates were similar between the two groups. For patients who receive these drugs repeatedly over months or years, the time savings from subcutaneous administration can meaningfully reduce the burden of treatment.
Infection Risk and Immune Monitoring
Because anti-CD20 drugs deplete B cells, they lower the body’s ability to fight certain infections. In a large study of more than 4,400 patients, about 28% experienced a severe infection requiring hospitalization within 18 months of starting rituximab, with most of those infections occurring in the first six months. Among cancer patients specifically, the rate of severe infections jumped from about 19% in the six months before rituximab to about 25% in the six months after.
A key concern with long-term use is the gradual decline of immunoglobulin levels, the circulating antibodies that protect against everyday pathogens. Higher cumulative doses of rituximab have been linked to lower IgG levels. In one study of MS patients, cumulative doses above four grams were independently associated with increased risk of both serious and outpatient infections, and IgG levels below 500 mg/dL roughly tripled the risk of serious infection. Interestingly, a smaller study in patients with inflammatory neurological diseases found no clear relationship between low immunoglobulin levels and infection risk in either the rituximab or ocrelizumab groups, suggesting the picture may differ depending on the patient population and other factors at play.
Clinicians generally monitor immunoglobulin levels periodically during treatment, especially in patients receiving repeated courses over years. When levels drop significantly, some patients receive immunoglobulin replacement therapy to shore up their defenses.
Hepatitis B Reactivation
One of the most serious safety concerns with anti-CD20 therapy is the risk of reactivating hepatitis B virus in people who carry it, even if the infection was previously controlled. The FDA issued a warning about this risk in 2013 and now recommends screening all patients for hepatitis B before starting rituximab.
A meta-analysis quantified the risk: patients receiving rituximab-based therapy had roughly twice the rate of hepatitis B reactivation compared with those on chemotherapy alone. For patients who tested positive only for a past-exposure marker called core antibody (meaning the virus was thought to be cleared), the risk was even more pronounced, with reactivation rates more than five times higher with rituximab-containing regimens. Current guidelines recommend antiviral prophylaxis before chemotherapy for high-risk patients and monitoring of viral levels throughout treatment. Progressive multifocal leukoencephalopathy, a rare and often fatal brain infection caused by reactivation of JC polyomavirus, has also been reported in rituximab-treated patients, though the absolute risk appears to be low.
Vaccines and Anti-CD20 Therapy
The COVID-19 pandemic brought sharp attention to a practical problem: people on anti-CD20 drugs often mount weak antibody responses to vaccines. In one study, most patients receiving anti-CD20 therapy did not show an increase in spike-specific B cells or antibodies even after a third dose of COVID-19 vaccine, in contrast with healthy controls who responded robustly.
The good news is that the suppression appears to be reversible. Research in MS patients found that the inhibition of vaccine antibody responses was transient, with antibody production becoming more pronounced once more than 18 months had passed since the last anti-CD20 infusion. B-cell counts also began recovering around the same time frame. This has practical implications for treatment planning. When possible, clinicians try to time vaccinations for periods when B-cell counts have partially recovered, or they schedule important vaccinations before starting anti-CD20 therapy. T-cell responses to vaccines may be partially preserved even when antibody responses are blunted, which offers some degree of protection, though the clinical significance of this is still being studied.
Biosimilars and Access
Rituximab’s original patent has expired, and several biosimilar versions are now available worldwide. A biosimilar is a near-identical copy of a biologic drug that has been shown through rigorous testing to match the original in safety and effectiveness. In one study comparing a rituximab biosimilar to the reference product in patients with non-Hodgkin lymphoma and CLL, the overall response rate was 85% in both groups, with comparable rates of complete and partial responses and a similar safety profile. The availability of biosimilars has driven down costs and expanded access in countries where the original brand-name product was prohibitively expensive, a meaningful development for diseases that require repeated infusions over long periods.
Bispecific CAR T Cells Targeting CD20
One limitation of standard anti-CD20 antibodies is that cancer cells can sometimes escape by losing CD20 from their surface. Researchers have responded by developing CAR T cells, engineered immune cells that are programmed to hunt specific targets, designed to recognize both CD20 and CD19 simultaneously. In preclinical work, these bispecific CAR T cells activated fully when they encountered either target on a cancer cell, functioning as an “or” gate: the cell did not need to display both markers to be killed. When tested in mice bearing a type of pediatric leukemia with mixed CD19-positive and CD20-negative cells, the bispecific CAR T cells cleared the disease from blood and bone marrow, while CAR T cells targeting CD20 alone left the CD20-negative cancer cells behind. This dual-targeting approach is being explored as a way to reduce the risk of relapse through antigen escape, one of the major challenges in targeted immunotherapy.